Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma

Cancer Science

Volumn 103, Issue 2, 2012, Pages 233-238

  Nakajima, Takako E ^a,b   Yoshida, Hiroshi ^a,c   Okamoto, Naoko ^d,e   Nagashima, Kengo ^f   Taniguchi, Hirokazu ^a   Yamada, Yasuhide ^a   Shimoda, Tadakazu ^a   Masutomi, Kenkichi ^d,g  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ASAHI GENERAL HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^e TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^f JOSAI UNIVERSITY   (Japan)

^g JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CISPLATIN; FLUOROURACIL; GUANINE NUCLEOTIDE BINDING PROTEIN; HERMES ANTIGEN; NUCLEOSTEMIN; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CARCINOGENESIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RETROSPECTIVE STUDY; TUMOR CELL;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; EPITHELIAL-MESENCHYMAL TRANSITION; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; GTP-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PEPTIDES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TWIST TRANSCRIPTION FACTOR;

EID: 84856447823     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02142.x     Document Type: Article

References (21)

1. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002; 99: 860-8.
2. Morita M, Yoshida R, Ikeda K et al. Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. Surgery 2008; 143: 499-508.
3. Tepper J, Krasna MJ, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-92.
4. Medical-Research-Council-Oesophageal-Cancer-Working-Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359: 1727-33.
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-8.
6. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-60.
7. Rich JN, Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell 2007; 1: 353-5.
8. Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402.
9. Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell 2007; 1: 241-2.
10. Hermann PC, Huber SL, Herrler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-23.
11. Mani SA, Guo W, Liao MJ et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
12. Nagahama Y, Ueno M, Miyamoto S et al. PSF1, a DNA replication factor expressed widely in stem and progenitor cells, drives tumorigenic and metastatic properties. Cancer Res 2010; 70: 1215-24.
13. Tsai RY, McKay RD. A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev 2002; 16: 2991-3003.
14. Baddoo M, Hill K, Wilkinson R et al. Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J Cell Biochem 2003; 89: 1235-49.
15. Tamase A, Muraguchi T, Naka K et al. Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci U S A 2009; 106: 17163-8.
16. Okamoto N, Yasukawa M, Nguyen C et al. Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A 2011; doi: 10.1073/pnas.1015171108 [Epub ahead of print].
17. Yang J, Mani SA, Donaher JL et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004; 117: 927-39.
18. Union-Internationale-Contre-le-Cancer. TNM Classification of Malignant Tumours, 6th edn. Wilmington, NC: Wisky-Liss, 2002.
19. The-Japan-Esophageal-Society. Guide Lines for Clinical and Pathological Studies on Carcinoma of the Esophagus, 10th edn. Tokyo: Kanehara & Co. Ltd., 2008.
20. Xie F, Li K, Ouyang X. Twist, an independent prognostic marker for predicting distant metastasis and survival rates of esophageal squamous cell carcinoma patients. Clin Exp Metastasis 2009; 26: 1025-32.
21. Yuen HF, Chan YP, Wong ML et al. Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis. J Clin Pathol 2007; 60: 510-4.